A number of firms have modified their ratings and price targets on shares of DexCom (NASDAQ: DXCM) recently:

  • 8/9/2017 – DexCom was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 8/8/2017 – DexCom had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $90.00 price target on the stock, down previously from $105.00.
  • 8/4/2017 – DexCom was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “DexCom reported narrower-than-expected loss in the second quarter. We believe the company’s margins will continue to be under pressure in the coming quarters, owing to high product development costs and rising expenditures on research & development. Specifically, the company is expected to have lower margins on transmitter sales (in spite of the cost reduction initiatives). Additionally, cutthroat competition in the market for blood glucose monitoring devices is a major headwind. In the past one year, DexCom has underperformed the broader industry in terms of price. On the positive side, the glucose monitoring market represents significant commercial opportunity for DexCom. The company has also signed collaborative agreements with several companies, which should not only bring in cash, but also help expand its product portfolio.”
  • 8/2/2017 – DexCom was upgraded by analysts at TheStreet from a “d” rating to a “c-” rating.
  • 8/2/2017 – DexCom had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $83.00 price target on the stock, down previously from $95.00.
  • 8/2/2017 – DexCom was given a new $92.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 8/2/2017 – DexCom had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $90.00 price target on the stock, down previously from $105.00.
  • 8/1/2017 – DexCom was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 7/24/2017 – DexCom was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/18/2017 – DexCom was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “In the past one year, DexCom has underperformed the broader industry in terms of price. Furthermore, a disappointing estimate revision trend indicates looming concerns ahead. DexCom reported narrower-than-expected loss in the first quarter. We believe the company’s margins will continue to be under pressure in the coming quarters owing to high product development costs and rising expenditures on research & development. Specifically, the company is expected to have lower margins on transmitter sales (in spite of the cost reduction initiatives). Additionally, cutthroat competition in the market for blood glucose monitoring devices is a major headwind. On the positive side, the glucose monitoring market represents significant commercial opportunity for DexCom. The company has also signed collaborative agreements with several companies, which should not only bring in cash but also help expand its product portfolio.”
  • 7/14/2017 – DexCom had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $90.00 price target on the stock.
  • 7/13/2017 – DexCom had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $105.00 price target on the stock.
  • 7/12/2017 – DexCom had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $78.00 price target on the stock.
  • 7/5/2017 – DexCom was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/21/2017 – DexCom was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/15/2017 – DexCom was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

DexCom, Inc. (DXCM) opened at 69.80 on Friday. DexCom, Inc. has a one year low of $57.68 and a one year high of $96.38. The stock’s market capitalization is $6.04 billion. The firm has a 50-day moving average of $71.38 and a 200 day moving average of $75.25.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. DexCom’s revenue was up 24.3% on a year-over-year basis. During the same period last year, the firm posted ($0.24) EPS. On average, equities research analysts anticipate that DexCom, Inc. will post ($0.77) earnings per share for the current fiscal year.

In related news, EVP Richard Doubleday sold 3,182 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $68.29, for a total value of $217,298.78. Following the completion of the transaction, the executive vice president now directly owns 72,395 shares of the company’s stock, valued at approximately $4,943,854.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 8,649 shares of the stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $68.39, for a total transaction of $591,505.11. Following the completion of the transaction, the chief executive officer now directly owns 347,329 shares of the company’s stock, valued at $23,753,830.31. The disclosure for this sale can be found here. Insiders sold a total of 33,131 shares of company stock valued at $2,318,443 over the last ninety days. 1.70% of the stock is currently owned by insiders.

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Receive News & Ratings for DexCom Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.